[S03AA02, tetracycline, The risk or severity of pseudotumor cerebri can be increased when Tetracycline is combined with Palovarotene.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Palovarotene.]
[J01FA08, troleandomycin, The serum concentration of Palovarotene can be increased when it is combined with Troleandomycin.]
[A10BH05, linagliptin, The metabolism of Palovarotene can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The serum concentration of Palovarotene can be increased when it is combined with Boceprevir.]
[J05AP02, telaprevir, The serum concentration of Palovarotene can be increased when it is combined with Telaprevir.]
[C08DA01, verapamil, The metabolism of Palovarotene can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Palovarotene can be decreased when combined with Viloxazine.]
[S01XA02, vitamin A, The risk or severity of adverse effects can be increased when Vitamin A is combined with Palovarotene.]
[J05AE02, indinavir, The serum concentration of Palovarotene can be increased when it is combined with Indinavir.]
[L01ED01, crizotinib, The metabolism of Palovarotene can be decreased when combined with Crizotinib.]
[N05AE04, ziprasidone, The metabolism of Palovarotene can be decreased when combined with Ziprasidone.]
[G03AC10, drospirenone, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Palovarotene.]
[J02AC03, voriconazole, The serum concentration of Palovarotene can be increased when it is combined with Voriconazole.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Palovarotene.]
[V03AX03, cobicistat, The serum concentration of Palovarotene can be increased when it is combined with Cobicistat.]
[J05AJ02, elvitegravir, The serum concentration of Palovarotene can be increased when it is combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Palovarotene can be decreased when it is combined with Enzalutamide.]
[J05AE04, nelfinavir, The serum concentration of Palovarotene can be increased when it is combined with Nelfinavir.]
[L01EC02, dabrafenib, The serum concentration of Palovarotene can be decreased when it is combined with Dabrafenib.]
[J05AP05, simeprevir, The metabolism of Palovarotene can be decreased when combined with Simeprevir.]
[A16AA07, metreleptin, The metabolism of Palovarotene can be increased when combined with Metreleptin.]
[D05BB02, acitretin, The risk or severity of adverse effects can be increased when Acitretin is combined with Palovarotene.]
[J02AC05, isavuconazole, The metabolism of Palovarotene can be decreased when combined with Isavuconazole.]
[L01XX52, venetoclax, The metabolism of Palovarotene can be decreased when combined with Venetoclax.]
[L01EF02, ribociclib, The serum concentration of Palovarotene can be increased when it is combined with Ribociclib.]
[J05AE09, tipranavir, The serum concentration of Palovarotene can be increased when it is combined with Tipranavir.]
[L01EX10, midostaurin, The serum concentration of Palovarotene can be increased when it is combined with Midostaurin.]
[J05AG03, efavirenz, The serum concentration of Palovarotene can be increased when it is combined with Efavirenz.]
[L02BB05, apalutamide, The serum concentration of Palovarotene can be decreased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The serum concentration of Palovarotene can be decreased when it is combined with Carbamazepine.]
[L01XX62, ivosidenib, The metabolism of Palovarotene can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The serum concentration of Palovarotene can be increased when it is combined with Stiripentol.]
[J01AA13, eravacycline, The risk or severity of pseudotumor cerebri can be increased when Eravacycline is combined with Palovarotene.]
[J01AA14, sarecycline, The risk or severity of pseudotumor cerebri can be increased when Sarecycline is combined with Palovarotene.]
[J01AA15, omadacycline, The risk or severity of pseudotumor cerebri can be increased when Omadacycline is combined with Palovarotene.]
[J01FA09, clarithromycin, The serum concentration of Palovarotene can be increased when it is combined with Clarithromycin.]
[J01AA11, clomocycline, The risk or severity of pseudotumor cerebri can be increased when Clomocycline is combined with Palovarotene.]
[N07XX11, pitolisant, The serum concentration of Palovarotene can be decreased when it is combined with Pitolisant.]
[G03DB05, demegestone, The therapeutic efficacy of Demegestone can be decreased when used in combination with Palovarotene.]
[G03AC09, desogestrel, The therapeutic efficacy of Desogestrel can be decreased when used in combination with Palovarotene.]
[N03AX25, cenobamate, The serum concentration of Palovarotene can be decreased when it is combined with Cenobamate.]
[J05AE05, amprenavir, The serum concentration of Palovarotene can be increased when it is combined with Amprenavir.]
[G03DB08, dienogest, The therapeutic efficacy of Dienogest can be decreased when used in combination with Palovarotene.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Palovarotene.]
[C01BD07, dronedarone, The metabolism of Palovarotene can be decreased when combined with Dronedarone.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Palovarotene.]
[L04AC19, satralizumab, The serum concentration of Palovarotene can be decreased when it is combined with Satralizumab.]
[S01AA02, chlortetracycline, The risk or severity of pseudotumor cerebri can be increased when Chlortetracycline is combined with Palovarotene.]
[B06AC06, berotralstat, The metabolism of Palovarotene can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The serum concentration of Palovarotene can be increased when it is combined with Lonafarnib.]
[P03AX07, abametapir, The serum concentration of Palovarotene can be increased when it is combined with Abametapir.]
[L01XX73, sotorasib, The serum concentration of Palovarotene can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Palovarotene can be decreased when combined with Ciprofloxacin.]
[N06AX25, St. John's wort extract, The serum concentration of Palovarotene can be decreased when it is combined with St. John's Wort.]
[C01EB24, mavacamten, The serum concentration of Palovarotene can be decreased when it is combined with Mavacamten.]
[N05AH02, clozapine, The metabolism of Palovarotene can be decreased when combined with Clozapine.]
[H01AC08, somatrogon, The metabolism of Palovarotene can be increased when combined with Somatrogon.]
[S01AA13, fusidic acid, The metabolism of Palovarotene can be decreased when combined with Fusidic acid.]
[J01FA15, telithromycin, The serum concentration of Palovarotene can be increased when it is combined with Telithromycin.]
[J02AC02, itraconazole, The serum concentration of Palovarotene can be increased when it is combined with Itraconazole.]
[J02AC04, posaconazole, The serum concentration of Palovarotene can be increased when it is combined with Posaconazole.]
[D10AF04, meclocycline, The risk or severity of pseudotumor cerebri can be increased when Meclocycline is combined with Palovarotene.]
[S01XA18, cyclosporine, The metabolism of Palovarotene can be decreased when combined with Cyclosporine.]
[C03XA02, conivaptan, The serum concentration of Palovarotene can be increased when it is combined with Conivaptan.]
[G03XA01, danazol, The serum concentration of Palovarotene can be increased when it is combined with Danazol.]
[J01AA01, demeclocycline, The risk or severity of pseudotumor cerebri can be increased when Demeclocycline is combined with Palovarotene.]
[N06AX06, nefazodone, The serum concentration of Palovarotene can be increased when it is combined with Nefazodone.]
[S03BA01, dexamethasone, The serum concentration of Palovarotene can be decreased when it is combined with Dexamethasone.]
[L02AA01, diethylstilbestrol, The therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Palovarotene.]
[C08CA03, isradipine, The metabolism of Palovarotene can be decreased when combined with Isradipine.]
[J05AE08, atazanavir, The serum concentration of Palovarotene can be increased when it is combined with Atazanavir.]
[C08DB01, diltiazem, The metabolism of Palovarotene can be decreased when combined with Diltiazem.]
[S02AA12, rifamycin SV, The serum concentration of Palovarotene can be decreased when it is combined with Rifamycin.]
[J04AB05, rifapentine, The serum concentration of Palovarotene can be decreased when it is combined with Rifapentine.]
[A04AD12, aprepitant, The metabolism of Palovarotene can be decreased when combined with Aprepitant.]
[J01AA02, doxycycline, The risk or severity of pseudotumor cerebri can be increased when Doxycycline is combined with Palovarotene.]
[G01AF05, econazole, The serum concentration of Palovarotene can be increased when it is combined with Econazole.]
[J01AA12, tigecycline, The risk or severity of pseudotumor cerebri can be increased when Tigecycline is combined with Palovarotene.]
[C08CA12, mepirodipine, The metabolism of Palovarotene can be decreased when combined with Barnidipine.]
[N02CA02, ergotamine, The serum concentration of Palovarotene can be increased when it is combined with Ergotamine.]
[S01AA17, erythromycin, The metabolism of Palovarotene can be decreased when combined with Erythromycin.]
[G03CA03, estradiol, The therapeutic efficacy of Estradiol can be decreased when used in combination with Palovarotene.]
[L02AA03, ethinyl estradiol, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Palovarotene.]
[D05BB01, etretinate, The risk or severity of adverse effects can be increased when Etretinate is combined with Palovarotene.]
[R06AX12, terfenadine, The serum concentration of Palovarotene can be increased when it is combined with Terfenadine.]
[N06AB08, fluvoxamine, The metabolism of Palovarotene can be decreased when combined with Fluvoxamine.]
[J02AC01, fluconazole, The metabolism of Palovarotene can be decreased when combined with Fluconazole.]
[J05AE10, darunavir, The serum concentration of Palovarotene can be increased when it is combined with Darunavir.]
[G03XA02, gestrinone, The therapeutic efficacy of Gestrinone can be decreased when used in combination with Palovarotene.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Palovarotene.]
[C08CA10, nilvadipine, The metabolism of Palovarotene can be decreased when combined with Nilvadipine.]
[S01BA13, rimexolone, The serum concentration of Palovarotene can be decreased when it is combined with Rimexolone.]
[N06AX17, milnacipran, The metabolism of Palovarotene can be decreased when combined with Milnacipran.]
[J04AC01, isoniazid, The metabolism of Palovarotene can be decreased when combined with Isoniazid.]
[D10BA01, isotretinoin, The risk or severity of adverse effects can be increased when Isotretinoin is combined with Palovarotene.]
[J02AB02, ketoconazole, The serum concentration of Palovarotene can be increased when it is combined with Ketoconazole.]
[G03AD01, levonorgestrel, The therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Palovarotene.]
[C10AA02, lovastatin, The metabolism of Palovarotene can be decreased when combined with Lovastatin.]
[J01AA04, lymecycline, The risk or severity of pseudotumor cerebri can be increased when Lymecycline is combined with Palovarotene.]
[G03DC03, lynestrenol, The therapeutic efficacy of Lynestrenol can be decreased when used in combination with Palovarotene.]
[L01EA03, nilotinib, The serum concentration of Palovarotene can be increased when it is combined with Nilotinib.]
[J01AA05, methacycline, The risk or severity of pseudotumor cerebri can be increased when Metacycline is combined with Palovarotene.]
[H03BB02, methimazole, The serum concentration of Palovarotene can be increased when it is combined with Methimazole.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Methotrexate is combined with Palovarotene.]
[S02AA13, miconazole, The metabolism of Palovarotene can be decreased when combined with Miconazole.]
[J01AA08, minocycline, The risk or severity of pseudotumor cerebri can be increased when Minocycline is combined with Palovarotene.]
[L01XX23, mitotane, The serum concentration of Palovarotene can be decreased when it is combined with Mitotane.]
[C01BD01, amiodarone, The serum concentration of Palovarotene can be increased when it is combined with Amiodarone.]
[N03AB05, fosphenytoin, The serum concentration of Palovarotene can be decreased when it is combined with Fosphenytoin.]
[V03AB15, naloxone, The serum concentration of Palovarotene can be increased when it is combined with Naloxone.]
[N06AX23, desvenlafaxine, The metabolism of Palovarotene can be decreased when combined with Desvenlafaxine.]
[C08CA04, nicardipine, The metabolism of Palovarotene can be decreased when combined with Nicardipine.]
[G03DC02, norethindrone, The therapeutic efficacy of Norethisterone can be decreased when used in combination with Palovarotene.]
[G03AC07, norgestrienone, The therapeutic efficacy of Norgestrienone can be decreased when used in combination with Palovarotene.]
[S01AA04, oxytetracycline, The risk or severity of pseudotumor cerebri can be increased when Oxytetracycline is combined with Palovarotene.]
[G03DB06, chlormadinone, The therapeutic efficacy of Chlormadinone can be decreased when used in combination with Palovarotene.]
[N05CA01, pentobarbital, The serum concentration of Palovarotene can be decreased when it is combined with Pentobarbital.]
[N03AA02, phenobarbital, The serum concentration of Palovarotene can be decreased when it is combined with Phenobarbital.]
[N03AB02, phenytoin, The serum concentration of Palovarotene can be decreased when it is combined with Phenytoin.]
[L01XF02, alitretinoin, The risk or severity of adverse effects can be increased when Alitretinoin is combined with Palovarotene.]
[J05AE01, saquinavir, The serum concentration of Palovarotene can be increased when it is combined with Saquinavir.]
[J05AG02, delavirdine, The serum concentration of Palovarotene can be increased when it is combined with Delavirdine.]
[D05AX05, tazarotene, The risk or severity of adverse effects can be increased when Tazarotene is combined with Palovarotene.]
[J05AE03, ritonavir, The serum concentration of Palovarotene can be increased when it is combined with Ritonavir.]
[P01BA03, primaquine, The metabolism of Palovarotene can be decreased when combined with Primaquine.]
[N03AA03, primidone, The serum concentration of Palovarotene can be decreased when it is combined with Primidone.]
[J04AB02, rifampin, The serum concentration of Palovarotene can be decreased when it is combined with Rifampicin.]
[J01AA09, rolitetracycline, The risk or severity of pseudotumor cerebri can be increased when Rolitetracycline is combined with Palovarotene.]
[N03AG01, valproic acid, Valproic acid may increase the Pseudotumor Cerebri activities of Palovarotene.]
[H02CA04, levoketoconazole, The serum concentration of Palovarotene can be increased when it is combined with Levoketoconazole.]
